Cell-free DNA Testing Market is estimated to witness a CAGR of 26.5% by 2023 - Natera, Beijing Genomics Institute, Illumina, Guardant Health

Cell-free DNA Testing Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.

Market Analysis: The "Global Cell-free DNA Testing Market" is estimated to witness a CAGR of 26.5% during the forecast period 2017-2023. The market is analyzed based on three segments, namely test types, application, and regions.

Sample Copy Available at https://www.reportsweb.com/inquiry&RW00011868224/sample

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Test Types Analysis: The global cfDNA testing market by test type is segmented into cell-free fetal DNA tests (also called NIPT), circulating tumor DNA tests, and donor-derived cell-free DNA tests. Cell-free fetal DNA tests is the largest segment, as women are more career-oriented, and the trend is seen in western countries to start family at a late age. These lead to an increase in the average maternal age. Donor-derived cfDNA tests are the fastest growing segment. The rising number of organ donors, increasing transplantation procedures, increasing healthcare awareness have made them the fastest growing segment of the market. The market is also witnessing various acquisitions, agreements, and new product launches and collaborations among the top players, which is defining the future of the global cfDNA testing market.

Application Analysis: The global cfDNA testing market by application is segmented into Gynecology, Oncology, and Transplantation. Gynecology occupies the largest market share and transplantation is expected to be the fastest growing segment during the forecasted period.

Key Players: Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and other predominate & niche players.

Competitive Analysis: Currently, the cfDNA tests dominate the global cfDNA testing market. A lot of new players are focusing on this market to provide innovative tests with high accuracy and less turnaround time. Many major players in the market are launching new products to maintain their leadership in the market. Apart from this, the big players are acquiring small companies in the market to enhance their product portfolio and maintain their market leadership. For instance, in September 2016, LabCorp acquired Sequenom to strengthen its non-invasive prenatal testing product portfolio.

Place Direct Purchase Order Here: https://www.reportsweb.com/buy&RW00011868224/buy/2750

Table of Contents:

1 INDUSTRY OUTLOOK 9

2 Report Outline 11

3 Market Snapshot 13

4 Market Outlook 16

5 Market Characteristics 22

6 Test Types: Market Size and Analysis 28

7 Application: Market Size and Analysis 33

8 Regions: Market Size and Analysis 37

9 Competitive Landscape 45

10 Vendor Profiles 48
10.1 Natera, Inc. 48
10.1.1 Overview 48
10.1.2 Natera Inc.:Product offerings 48
10.1.3 NATERA, INC.: Recent Developments 49
10.1.4 Geographic Presence 52
10.1.5 Business Focus 52
10.1.6 SWOT Analysis 53
10.1.7 Business Strategy 53
10.2 Laboratory Corporation of America Holdings (LABCORP) 54
10.2.1 Overview 54
10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings 55
10.2.3 Laboratory Corporation Of America Holdings: Recent Developments 56
10.2.4 Business Unit 58
10.2.5 Geographic Presence 58
10.2.6 Business Focus 59
10.2.7 SWOT Analysis 59
10.2.8 Business Strategy 60
10.3 Illumina, Inc., 61
10.3.1 Overview 61
10.3.2 Illumina, INC: Product offerings 61
10.3.3 Illumina, INC: Recent Developments 62
10.3.4 Geographic Presence 66
10.3.5 Business Focus 66
10.3.6 SWOT Analysis 67
10.3.7 Business Strategy 67
10.4 BEIJING GENOMICS INSTITUTE 68
10.4.1 Overview 68
10.4.2 Beijing Genomics Institute: Product offerings 68
10.4.3 Beijing Genomics Institute: Recent Developments 69
10.4.4 Business Focus 69
10.4.5 SWOT Analysis 69
10.4.6 Business Strategy 70
10.5 F.Hoffmann-La Roche Ltd 71
10.5.1 Overview 71
10.5.2 F. Hoffmann-la Roche: Product Offerings 71
10.5.3 F. Hoffmann-la roche.: Recent Developments 72
10.5.4 Business Unit 75
10.5.5 Geographic Presence 76
10.5.6 Business Focus 76
10.5.7 SWOT Analysis 77
10.5.8 Business Strategy 77
Companies to Watch For 78
10.6 CareDx, Inc 78
10.6.1 Overview 78
10.6.2 caredx: Recent Developments 79
10.7 LifeCodexx AG 80
10.7.1 Overview 80
10.7.2 LifeCodexx AG: Recent Developments 80
10.8 Biocept, Inc. 81
10.8.1 Overview 81
10.8.2 Biocept, Inc.: Recent Developments 82
10.9 Quest Diagnostics 84
10.9.1 Overview 84
10.9.2 Quest Diagnostics: Recent Developments 85
10.10 Guardant Health 87
10.10.1 Overview 87
10.10.2 Guardant Health: Recent Developments 87
10.11 Inivata Limited 89
10.11.1 Overview 89
10.11.2 Inivata Limited: Recent Developments 89
10.12 Personal Genome Diagnostics 90
10.12.1 Overview 90
10.12.2 Personal Genome Diagnostics: Recent Developments 91
10.13 Trovagene 91
10.13.1 Overview 91
10.13.2 Trovagene, Inc.: Recent Developments 92

For more information about this report: https://www.reportsweb.com/reports/Cell-free-DNA-Testing-Market-Global-Drivers-Restraints-Opportunities-Trends-and-Forecasts-2017-2023

Contact Info:
Name: Sameer
Email: sales@reportsweb.com
Organization: ReportsWeb
Phone: +1-646-491-9876

Pune, India

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

This release was published on openPR.